title: Ventilatory strategies and adjunctive therapy in ARDS.
abstract: Acute respiratory distress syndrome, a diagnosis based on physiologic and radiological criteria, occurs commonly in critical care setting. A major challenge in evaluating therapies that may improve survival in ARDS is that it is not a single disease entity but, rather, numerous different diseases that result in endothelial injury, where the most obvious manifestation is within the lung resulting in pulmonary oedema. It has been shown that poor ventilatory technique that is injurious to the lungs can propagate systemic inflammatory response and adversely affect the mortality. The current data suggest that high tidal volumes with high plateau pressures are deleterious and a strategy of ventilation with lower tidal volumes and lower plateau pressure is associated with lower mortality. There may be a role for recruitment manoeuvres as well. Other forms of respiratory support still require further research. The present understanding of optimal ventilatory management and other adjunctive therapies are reviewed.
authors.affiliation: PICU, St. Mary's Hospital, London, United Kingdom.
authors.forename: Ajay R
authors.initials: AR
authors.lastname: Desai
authors.forename: Akash
authors.initials: A
authors.lastname: Deep
mesh_terms: D000280:Administration, Inhalation; D002648:Child; D015199:Extracorporeal Membrane Oxygenation; D005938:Glucocorticoids / Q000627:therapeutic use; D006612:High-Frequency Ventilation; D006801:Humans; D021061:Liquid Ventilation; D009569:Nitric Oxide / Q000008:administration & dosage; D010879:Piperazines / Q000627:therapeutic use; D011175:Positive-Pressure Respiration; D016684:Prone Position; D011663:Pulmonary Surfactants / Q000627:therapeutic use; D012123:Pulmonary Ventilation; D011687:Purines; D012121:Respiration, Artificial / Q000009:adverse effects* / Q000379:methods*; D012128:Respiratory Distress Syndrome / Q000209:etiology / Q000401:mortality / Q000503:physiopathology* / Q000628:therapy*; D019141:Respiratory System Agents / Q000627:therapeutic use*; D000068677:Sildenafil Citrate; D013450:Sulfones; D013990:Tidal Volume; D014665:Vasodilator Agents / Q000008:administration & dosage
chemical_list: D005938:Glucocorticoids; D010879:Piperazines; D011663:Pulmonary Surfactants; D011687:Purines; D019141:Respiratory System Agents; D013450:Sulfones; D014665:Vasodilator Agents; D009569:Nitric Oxide; D000068677:Sildenafil Citrate